Primary intestinal follicular lymphoma and premature atherosclerosis in a Japanese diabetic patient with atypical familial partial lipodystrophy

Internal Medicine

Volumn 53, Issue 8, 2014, Pages 851-858

  Iwanishi, Masanori ^a   Ebihara, Ken ^b   Kusakabe, Toru ^c   Washiyama, Miki ^a   Ito Kobayashi, Jun ^a   Nakamura, Fumiyasu ^a   Togawa, Takeshi ^a   Ozamoto, Yuki ^a   Hagiwara, Akeo ^a   Nakao, Kazuwa ^c  

^a Kusatsu General Hospital   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Familial partial lipodystrophy (FPL); Metabolic surgery; Premature atherosclerosis; Primary intestinal follicular lymphoma

Indexed keywords

ADIPONECTIN; C PEPTIDE; CD20 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; FLUORODEOXYGLUCOSE F 18; HEMOGLOBIN A1C; INSULIN; LEPTIN; PIOGLITAZONE; PROTEIN BCL 2;

ADULT; ARTICLE; ATHEROSCLEROSIS; BIOPSY; BODY COMPOSITION; BODY MASS; CASE REPORT; COLONOSCOPY; CORONARY ARTERY CALCIFICATION; DIABETES MELLITUS; DIABETIC RETINOPATHY; DUAL ENERGY X RAY ABSORPTIOMETRY; FAMILIAL PARTIAL LIPODYSTROPHY; FATTY LIVER; FEMALE; FOLLICULAR LYMPHOMA; GASTRECTOMY; GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE LYMPHOMA; JAPAN; LAMIN A C GENE; LAPAROSCOPY; LIPOATROPHY; LYMPH NODE METASTASIS; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE AGED; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA GENE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; SUBCUTANEOUS FAT DISORDER; ASIAN CONTINENTAL ANCESTRY GROUP; COMPLICATION; GASTROINTESTINAL TUMOR; INTESTINE TUMOR; OBESITY;

ASIAN CONTINENTAL ANCESTRY GROUP; ATHEROSCLEROSIS; DIABETES COMPLICATIONS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INTESTINAL NEOPLASMS; JAPAN; LIPODYSTROPHY, FAMILIAL PARTIAL; LYMPHOMA, FOLLICULAR; MIDDLE AGED; OBESITY;

EID: 84898607636     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.53.1713     Document Type: Article

References (36)

1. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 350: 1220-1234, 2004.
2. Agarwal AK, Garg A. Genetic disorders of adipose tissue development, differentiation and death. Annu Rev Genomics Hum Genet 7: 175-199, 2006.
3. Agarwal AK, Garg A. Genetic basis of lipodystrophies and management of metabolic complications. Annu Rev Med 57: 297-311, 2006.
4. Garg A. Lipodystrophies: Genetic and acquired body fat disorders. J Clin Endocrinol Metab 96: 3313-3325, 2011.
5. Dunnigan MG, Cochrane MA, Kelly A, Scott JW. Familial lipoatrophic diabetes with dominant transmission. Quarterly Journal of Medicine 169: 33-48, 1974.
6. Handelsman Y, Oral EA, Bloomgarden ZT, et al. The clinical approach to the detection of lipodystrophy an aace consensus statement. Endocr Pract 19: 107-116, 2013.
7. Vantyghem MC, Balavoine AS, Douillard C, et al. How to diagnose a lipodystrophy syndrome. Annales of Endocrinologie 73: 170-189, 2012.
8. Visser ME, Kropman E, Kranendonk ME. Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARgamma mutation (Y151C). Diabetogia 54: 1639-1644, 2011.
9. Ciudin A, Baena-Fustegueras JA, Fort JM, Encabo G, Lecube A. Successful treatment of the Dunnigan-type familial partial lipodystrophy with Roux-en-Y gastric bypass. Clinical Endocrinol 75: 403-404, 2011.
10. Utzschneider KM, Trence DL. Effectiveness of gastric bypass surgery in a patient with familial partial lipodystrophy. Diabetes Care 6: 1380-1382, 2006.
11. McGrath NM, FRACP M, Krishna G; MBChB, FRACS. Gastric bypass for insulin resistance due to lipodystrophy. Obes Surg 16: 1542-1544, 2006.
12. Joy T, Kennedy BA, Al-Attar S, Rutt BK, Hegele RA. Predicting abdominal adipose tissue among women with familial partial lipodystrophy. Metabolism 58: 828-834, 2009.
13. Mory PB, Crispim F, Freire MB, et al. Phenotypic diversity in patients with lipodystrophy associated with LMNA mutations. Eur J Endocrinol 167: 423-431, 2012.
14. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients in patients with lipodystrophies. J Clin Endocrinol Metab 87: 2395-2398, 2002.
15. McDuffie JR, Riggs PA, Calis KA, et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficieny. J Clin Endocrinol Metab 89: 4258-4263, 2004.
16. Aotani D, Ebihara K, Sawamoto N, et al. Functional magnetic resonance imaging analysis of food-related brain activity in patients with lipodystrophy undergoing leptin replacement therapy. J Clin Endocrinol Metab 97: 3663-3671, 2012.
17. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599, 2000.
18. Ebihara K, Kusakabe T, Hirata M, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 92: 532-541, 2007.
19. Moon HS, Dalamaga M, Kim SY, et al. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocrine Reviews 34: 1-36, 2013.
20. Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipostrophic mice. J Clin Invest 105: 271-278, 2000.
21. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: A review of current evidence. Endocrine Reviews 33: 547-594, 2012.
22. Bao Y, Giovannucci EL, Stampfer MJ, et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst 105: 95-103, 2013.
23. Mutoh M, Teraoka N, Takasu S, et al. Loss of adiponectin promotes intestinal carcinogenesis in min and wild-type mice. Gastroenterology 140: 2000-2008, 2011.
24. Matsumoto N, Suehio T, Nishiyama M, et al. A family with lipoatrophic diabetes, high frequency of type 2 diabetes mellitus nd cancer in the digestive organs. J. Japan Diab. Soc 43: 51-56, 2000.
25. Franceschini P, Barisone E, Signorile F, et al. Pre-B acute lymphoblastic leukemia in a patient with partial lipodystrophy and acanthosis nigricans. Panminerva Med 37: 248-251, 1995.
26. Shinkawa K, Nishikawa H, Mori T, Kawai H, Yoshida Y. Case of congenital generalized lipodystrophy associated with papillary serous cysadenocarcinoma. Horumon To Rinsho 25: 888-895, 1977 (in Japanese).
27. Conroy SM, Maskarinec G, Morimoto Y, et al. Non-Hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: The multiethnic cohort. Cancer Epidemiol Biomarkers Prev 1: 1-24, 2013.
28. Bereziat V, Cervera P, Le Dour C, et al; The Lipodystrophy Study Group. LMNA mutations induce a non-inflammatory fibrosis and a brown fat-like dystrophy of enlarged cervical adipose tissue. Am J Pathol 179: 2443-2453, 2011.
29. Gandotra S, Dour CL, Bottomley W, et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med 364: 740-748, 2011.
30. Garg A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 85: 1776, 2000.
31. Hegele RA. Premature atherosclerosis associated with monogenic insulin resistance. Circulation 103: 2225-2229, 2001.
32. Bidault G, Garcia M, Vantyghem M-C, et al. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction. Arterioscler Thromb Vasc Biol 33: 1-10, 2013.
33. Auclair M, Vigouroux C, Boccara F, et al. Peroxisome proliferator-activated receptor-γmutations responsible for lipodystrophy with severe hypertension activate the cellular reninangiotensin system. Arterioscler Thromb Vasc Biol 33: 829-838, 2013.
34. Iwanishi M, Ebihara K, Kusakabe T, et al. Premature atherosclerosis in a japanese diabetic patient with atypical familial partial lipodystrophy and hypertriglyceridemia. Intern Med 51: 2573-2579, 2012.
35. Iwanishi M, Ebihara K, Kusakabe T, et al. Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy. Metabolism 58: 1681-1687, 2009.
36. Arioglu EA, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 133: 263-274, 2000.